InvestorsHub Logo
Followers 135
Posts 13928
Boards Moderated 0
Alias Born 09/05/2013

Re: medicinecat post# 3297

Monday, 02/22/2021 2:05:28 PM

Monday, February 22, 2021 2:05:28 PM

Post# of 9703
To be fair...

"MindMed and Liechti Lab Announce R&D Collaboration On Psilocybin":
Sep 24, 2020

MindMed Collaborating On Study Comparing Effects Induced By LSD and Psilocybin Under Exclusive License Agreement With University Hospital Basel Liechti Lab


https://www.prnewswire.com/news-releases/mindmed-and-liechti-lab-announce-rd-collaboration-on-psilocybin-301137184.html

"MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience":
Jan. 14, 2021

MindMed Co-CEO J.R. Rahn said, “Rob has been an integral advisor to MindMed on Project Lucy and in preparing our meetings with the FDA, and we are honored he is now joining us on the senior leadership team. We are excited to attract such top tier talent from the psychedelic drug development community. The entire MindMed team is looking forward to exploring potential additional programs evaluating psilocybin and other psychedelics backed by Rob’s recent experience and expertise gaining a breakthrough therapy designation at FDA for a psychedelic assisted therapy.”


https://mindmed.co/news/press-release/mindmed-adds-chief-development-officer-with-fda-phase-2-psilocybin-clinical-trial-experience/
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MNMD News